Today: 19 May 2026
Browse Category

NYSE:MDT 28 June 2025 - 16 May 2026

Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific shares fell 1.6% to $92.33 Thursday, ending a four-day rally on heavy volume after the company completed its acquisition of Nalu Medical. The stock underperformed sector peers as investors awaited fourth-quarter results due Feb. 4 and looked for updates on recent deal activity, including the $14.5 billion Penumbra purchase.
30 January 2026
······
Medtronic (MDT) Stock Update: Dividend Timing, MiniMed IPO Catalyst, and What Investors Should Watch Before Monday’s Open

Medtronic (MDT) Stock Update: Dividend Timing, MiniMed IPO Catalyst, and What Investors Should Watch Before Monday’s Open

Medtronic (MDT) closed at $96.52 on the New York Stock Exchange after a slight pullback post-Christmas. No new company press releases appeared in the past 48 hours, though filings showed institutional activity and media highlighted Medtronic’s role in surgical robotics. The next $0.71 dividend is payable Jan. 16 to shareholders of record as of Dec. 26.
28 December 2025
·
Medtronic (MDT) Stock After Hours on Dec. 24, 2025: FDA Class I Recall Headline, Options Surge, Dividend Timing, and What to Watch Before Markets Reopen

Medtronic (MDT) Stock After Hours on Dec. 24, 2025: FDA Class I Recall Headline, Options Surge, Dividend Timing, and What to Watch Before Markets Reopen

Medtronic closed at $97.27 on Dec. 24, 2025, with light volume ahead of the Christmas holiday. After-hours trading showed a slight uptick to $97.45. The FDA classified Medtronic’s recall of certain DLP Left Heart Vent Catheters as Class I, citing risk of serious injury or death. Medtronic reported three serious injuries and no deaths linked to the issue.
25 December 2025
Medtronic PLC (MDT) Stock Outlook December 7, 2025: Price, Dividend, Hugo Robot FDA Win and 2026 Forecast

Medtronic PLC (MDT) Stock Outlook December 7, 2025: Price, Dividend, Hugo Robot FDA Win and 2026 Forecast

Medtronic shares closed at $101.36 on Dec. 5, 2025, up 18.8% over the past year and outpacing the S&P 500. The company reported strong fiscal Q2 results, raised guidance, and announced new FDA clearances for its Hugo surgical robot and Altaviva device. Elliott Investment Management became a top shareholder, prompting board changes and a planned Diabetes business spin-off. Dividend yield stands at about 2.8%.
7 December 2025
·
Medtronic (MDT) Stock News Today: Hugo Robot FDA Clearance, Diabetes Spin-Off and Dividend Strength Shape 2026 Outlook

Medtronic (MDT) Stock News Today: Hugo Robot FDA Clearance, Diabetes Spin-Off and Dividend Strength Shape 2026 Outlook

Medtronic closed at $101.36–$101.39 on December 5, with a market cap near $130 billion and a P/E ratio of 27.4. Wall Street Zen downgraded the stock to “Hold” on December 6, citing limited near-term upside after a 30% year-to-date gain. Amundi raised its stake by 18.8% in Q2, while Tema ETFs disclosed a new position. The average analyst price target stands at $110–$111.
6 December 2025
·
Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Medtronic Stock Jumps Above $100 After Q2 FY26 Beat and Raised Outlook on 18 November 2025

Medtronic shares jumped 4–5% to around $100–101 late Tuesday morning, hitting a three-year high after the company beat fiscal Q2 2026 earnings and revenue forecasts and raised its full-year outlook. Revenue rose 6.6% to $9.0 billion, with adjusted EPS of $1.36 topping analyst estimates. The rally pushed Medtronic’s market cap to about $129 billion. Demand for heart and diabetes devices drove the gains.
18 November 2025
··
Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Medtronic reported Q2 FY26 revenue of $8.96 billion, up 6.6% year over year, and non-GAAP EPS of $1.36, beating Wall Street estimates. Shares rose 4–5% intraday. Cardiac ablation revenue jumped 71% globally, with 128% growth in the U.S. The company raised its full-year outlook after its fourth straight quarter of beating consensus EPS.
18 November 2025
···
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

CSL will cut up to 15% of its workforce and spin off its vaccine unit, targeting $500–550 million in annual savings. Medtronic agreed to add two board members and form new committees after Elliott Investment Management took a major stake. Merck KGaA and Skyhawk Therapeutics announced a neurological drug pact worth up to $2 billion. Pfizer, Bristol Myers Squibb, and Regeneron reported improved Q2 2025 earnings.
20 August 2025
·····
Robotics and Automation Trends 2025: Industry Breakthroughs and Market Outlook (Updated: June 27th, 2025)

Robotics and Automation Trends 2025: Industry Breakthroughs and Market Outlook (Updated: June 27th, 2025)

New industrial robot installations reached $16.5 billion in 2024, with over 4.28 million robots active in factories worldwide. Asia led 2023 installations, accounting for 70%, and China alone made up 51%. Amazon operated about 800,000 mobile robots in its fulfillment centers by 2024. Global robot density hit 150 per 10,000 manufacturing workers in 2023, with South Korea surpassing 1,000.
28 June 2025
········

Stock Market Today

  • 3 TSX Stocks Positioned for Higher-for-Longer Interest Rates
    May 18, 2026, 11:23 PM EDT. Canadian Imperial Bank of Commerce (TSX:CM), Sun Life Financial (TSX:SLF), and Alaris Equity Partners Income Trust (TSX:AD.UN) stand to benefit from the Bank of Canada's higher-for-longer interest rate environment. CIBC, Canada's fifth-largest bank, saw a 24.25% gain year-to-date and posted a 43% rise in net income in Q1 fiscal 2026, supported by increased lending spreads. Sun Life Financial benefits from higher yields on fixed-income assets funded by premiums and has raised dividends for five consecutive years, boasting a 3.72% yield. Alaris Equity Partners provides non-control permanent equity capital mainly to profitable private mid-market companies, leveraging inflation-linked revenues. With the Bank of Canada's benchmark rate currently at 2.25% and risks of further hikes, these firms' business models and dividend reliability position them well amid economic uncertainties.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Go toTop